Michel Bolla

Pulmonary and Respiratory Medicine · 2001–2017

A researcher in the Science corpus: 17 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Michel Bolla trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. A. Billis

Who trusts Michel Bolla overall

  1. A. Heidenreich
  2. M. Hallek
  3. N. Mottet

Papers from Michel Bolla's perspective

Ordered by how strongly the researchers Michel Bolla trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
  2. Screening and prostate-cancer mortality in a randomized European study. (New England Journal of Medicine)
  3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
  4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (New England Journal of Medicine)
  5. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer (New England Journal of Medicine)
  6. Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
  7. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study (The Lancet)
  8. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. (Journal of Clinical Oncology)
  9. International variation in prostate cancer incidence and mortality rates. (European Urology)
  10. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. (Journal of the National Cancer Institute)

Their papers